secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-07-21T23:59:59+00:00
Accession:  0001104659-25-069149
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel submits pre-sNDA package to FDA for IGALMI outpatient label expansion
-----------------------------------------------------------------------------

- Pre-sNDA meeting package submitted July 21, 2025 for IGALMI (BXCL501) outpatient use.
- FDA meeting scheduled for August 20, 2025 to align on sNDA content and format.
- Expansion targets acute agitation in schizophrenia or bipolar disorders at-home setting.
- Plans to reconfirm prior Type C meeting (March 6, 2024) support for 120 mcg dose development.
- sNDA submission preparation ongoing; no guarantee of FDA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925069149/0001104659-25-069149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925069149/tm2521267d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-069149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer